Docket

38077

Eli Lilly Canada Inc. v. Teva Canada Limited

(Federal Court) (Civil) (By Leave)

(Sealing order) (Certain information not available to the public)

Judgments on applications for leave to appeal are rendered by the Court, but are not necessarily unanimous.

Proceedings
Date Proceeding Filed By
(if applicable)
2019-04-25 Close file on Leave
2019-04-25 Reconsideration not accepted for filing, Letter from Registrar
2019-01-09 Correspondence received from, (Letter Form), the applicant, pursuant to Rule 92.1 of the Rules of the Supreme Court of Canada, indicating that another application for leave to appeal (38471) is relevant to their motion for reconsideration and should be taken into account. Eli Lilly Canada Inc.
2018-12-21 Correspondence received from, (Letter Form), Change of address for agents of the Respondent. Teva Canada Limited
2018-12-12 Letter acknowledging receipt of an incomplete motion for reconsideration
2018-12-10 Motion for reconsideration of the application for leave to appeal, (Book Form), 4 copies missing (received 2018-12-17), Completed on: 2018-12-18 Eli Lilly Canada Inc.
2018-11-09 Copy of formal judgment sent to Registrar of the Court of Appeal and all parties
2018-11-09 Judgment on leave sent to the parties
2018-11-08 Judgment of the Court on the application for leave to appeal,
The application for leave to appeal from the judgment of the Federal Court of Appeal, Number A-71-17, 2018 FCA 53, dated February 22, 2018, is dismissed with costs.
Dismissed, with costs
2018-10-01 All materials on application for leave submitted to the Judges, CJ Row Mar, for consideration by the Court
2018-06-05 Certificate (on limitations to public access), (Letter Form), 23B Eli Lilly Canada Inc.
2018-06-04 Applicant's reply to respondent's argument, (Book Form), 23B required-rec'd 2018/06/05, Completed on: 2018-06-05 Eli Lilly Canada Inc.
2018-05-23 Notice of name, (Letter Form) Teva Canada Limited
2018-05-23 Certificate (on limitations to public access), (Letter Form), 23B Teva Canada Limited
2018-05-23 Certificate (on limitations to public access), (Letter Form), 23A Teva Canada Limited
2018-05-23 Respondent's response on the application for leave to appeal, (Book Form), Completed on: 2018-05-23 Teva Canada Limited
2018-04-30 Letter acknowledging receipt of a complete application for leave to appeal, FILE OPENED 2018/04/30
2018-04-23 Certificate (on limitations to public access), (Letter Form), 23B Eli Lilly Canada Inc.
2018-04-23 Certificate (on limitations to public access), (Letter Form), 23A Eli Lilly Canada Inc.
2018-04-23 Notice of name, (Letter Form) Eli Lilly Canada Inc.
2018-04-23 Application for leave to appeal, (Book Form), (4 volumes), Volumes 2 and 4 sealed; 2 redacted copies of each filed 2018/04/23, Completed on: 2018-04-23 Eli Lilly Canada Inc.